Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT – General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities. This work examined quality of life (QoL) among patients with relapsed/refractory diffuse large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy – Lymphoma and EuroQoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor maintained their QoL over the course of treatment. Grade ≥3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts. Clinical trial registration: NCT02227251 (ClinicalTrials.gov)
Authors
- Brian Thomas Hill (ORCID: https://orcid.org/0000-0001-8781-3327)
- Nagesh Kalakonda (ORCID: https://orcid.org/0000-0002-5300-1360)
- Sylvain Choquet (ORCID: https://orcid.org/0000-0002-7791-0470)
- Krzysztof Warzocha (ORCID: https://orcid.org/0000-0002-2396-3905)
- D. Tomaras
- Patrick Daniele (ORCID: https://orcid.org/0000-0002-7996-4472)
- Catherine Thiéblemont (ORCID: https://orcid.org/0000-0002-9941-2448)
- Ronit Gurion (ORCID: https://orcid.org/0009-0002-1838-5466)
- Sharon Shacham
- Joost S.P. Vermaat (ORCID: https://orcid.org/0000-0002-1628-6256)
- Matthew Ku (ORCID: https://orcid.org/0000-0002-9289-1335)
- Nada Hamad (ORCID: https://orcid.org/0000-0001-7929-1450)
- Andre Henri Goy (ORCID: https://orcid.org/0000-0001-5125-6522)
- Gabriel Tremblay (ORCID: https://orcid.org/0000-0001-9001-3128)
- Ãgnes Nagy (ORCID: https://orcid.org/0000-0002-7639-0987)
- Éric Van Den Neste
- Michael Kauffman
- Miguel Ángel Canales Albendea
- George Follows
- Fritz Offner (ORCID: https://orcid.org/0000-0001-6320-6020)
- Michael Schuster
- FEDERICA CAVALLO
- John Kuruvilla
- Ulrich Jäger
- Theodoros P Vasilakopoulos
- Sameer Bakhshi
- Jatin Shah
- Marie Maerevoet
- Reda Bouabdallah
- Josee Zijlstra
- Priyanka Samal
- Juan Manuel Sancho
- Miklós Egyed
- Paolo Caimi
- Rene-Olivier Casasnovas
- Fátima de la Cruz
Publication Details
- Journal
- Figshare
- Published
- 2026-11-12
- DOI
- https://doi.org/10.6084/m9.figshare.34998583
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00